Immunitybio, Inc. 8-K Filing
Ticker: IBRX · Form: 8-K · Filed: Dec 12, 2025 · CIK: 1326110
| Field | Detail |
|---|---|
| Company | Immunitybio, Inc. (IBRX) |
| Form Type | 8-K |
| Filed Date | Dec 12, 2025 |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Immunitybio, Inc. (ticker: IBRX) to the SEC on Dec 12, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.0001 (ch registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select).
How long is this filing?
Immunitybio, Inc.'s 8-K filing is 1 pages with approximately 434 words. Estimated reading time is 2 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 434 words · 2 min read · ~1 pages · Grade level 10.5 · Accepted 2025-12-12 07:01:54
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share IBRX The Nasdaq Global Select
Filing Documents
- ibrx-20251212.htm (8-K) — 28KB
- ibrx-202512128xkexhibit991.htm (EX-99.1) — 24KB
- immunitybio-logox2024xcolo.jpg (GRAPHIC) — 31KB
- 0001326110-25-000143.txt ( ) — 214KB
- ibrx-20251212.xsd (EX-101.SCH) — 2KB
- ibrx-20251212_lab.xml (EX-101.LAB) — 21KB
- ibrx-20251212_pre.xml (EX-101.PRE) — 12KB
- ibrx-20251212_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On December 12, 2025, ImmunityBio, Inc. issued a press release announcing certain regulatory updates. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 8.01 by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description of Exhibit 99.1* Press release dated December 12, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). _______________ * Filed herewith.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMMUNITYBIO, INC. Registrant Date: December 12, 2025 By: /s/ Richard Adcock Richard Adcock President and Chief Executive Officer